RN0191 / Ikaria Biosci - LARVOL DELTA

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Shanghai Rona Therapeutics Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Sep 2024 | Trial primary completion date: Dec 2024 ➔ Jul 2024

Trial completion • Trial completion date • Trial primary completion date

A Novel RNA Interference Agent RN0191 Lowering Proprotein Convertase Subtilisin/Kexin Type 9, Low-density Lipoprotein Cholesterol and Other Lipid Biomarkers in Healthy Volunteers with Elevated LDL Cholesterol: A Randomized, Single-blind, Placebo-controlled, Phase 1 Trial (AHA 2024) - P1 | "The preliminary safety and efficacy profile of RN0191 underscoring its comprehensive lipid-lowering capacity as a promising therapeutic candidate for managing dyslipidemia."

Biomarker • Clinical • P1 data • Coronary Artery Disease • Dyslipidemia • Heart Failure • Metabolic Disorders

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Shanghai Rona Therapeutics Co., Ltd. | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date

Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Ikaria Bioscience Pty Ltd | Recruiting ➔ Completed | Trial primary completion date: Jul 2024 ➔ Feb 2024

Trial completion • Trial primary completion date • Dyslipidemia

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Ikaria Bioscience Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Ikaria Bioscience Pty Ltd

Trial completion date • Trial initiation date • Trial primary completion date

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Ikaria Bioscience Pty Ltd

New P1 trial

Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Ikaria Bioscience Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia

Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Ikaria Bioscience Pty Ltd

New P1 trial • Dyslipidemia